facebook
twitter
rss
account
search
search

Avastin voted down at FDA hearing

June 30, 2011 at 2:03 AM   |   Comments

WASHINGTON, June 30 (UPI) -- Patients spoke at a hearing in Washington in support of using Avastin for breast cancer, but federal regulators voted against using the drug for that purpose.

The Food and Drug Administration's Oncologic Drugs Advisory Committee voted 12-1 last July to strip Avastin's approval as a breast cancer drug because the drug was not improving the survival rate for women with breast cancer while at the same time exposing them to dangerous side effects.

At the hearing Wednesday, Genentech, a subsidiary of Roche, defended its research, saying certain patients respond especially well and side effects, while potentially serious, are no worse than with other breast cancer drugs, CNN reported.

An expert said said for some women there are no better treatments available than Avastin, an approved breast cancer drug in Europe.

The drug will remain on the market for other cancer treatments, but if the FDA follows the panel's recommendation insurance companies wouldn't cover it for breast cancer patients and the cost of the drug -- about $100,000 a year -- may be too high for them to pay for themselves, CNN said.

© 2011 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Recommended Stories
Most Popular
1
Cheesecake Factory is America's most unhealthy food franchise
2
Another mosquito pool in Boston tests positive for West Nile
3
Florida health officials warn of flesh-eating bacteria
4
CDC: Ebola not a significant threat to United States
5
Skin cancer is 'major public health problem,' surgeon general says
Trending News
Video
x
Feedback